Booth No: M212
TaiGen is a research-based & market-driven pharmaceutical company. Taigexyn®, a novel antibiotic, is one of the first NCEs developed by a Taiwan company that received approval and launched in China and Taiwan.
Furaprevir is a HCV NS3/4A protease inhibitor. TaiGen and HEC Pharmaceutical built up a JV for an all-oral interferon-free treatment of HCV in Greater China, entering phase III trial now.
TG-1000, a novel antiviral for influenza, targets IND filing in China, US, Japan and Korea from 2019.
Exhibitors you may be interested in